ADZENYS XR-ODT Trademark

Trademark Overview

On Monday, December 14, 2015, a trademark application was filed for ADZENYS XR-ODT with the United States Patent and Trademark Office. The USPTO has given the ADZENYS XR-ODT trademark a serial number of 86847760. The federal status of this trademark filing is SECTION 8 - ACCEPTED as of Monday, September 26, 2022. This trademark is owned by Neos Therapeutics, Inc.. The ADZENYS XR-ODT trademark is filed in the Pharmaceutical Products category with the following description:

Prescription pharmaceutical preparations for the treatment of disease and disorders of the central nervous system, excluding pharmaceutical preparations for the prevention and treatment of disorders of the immune system; pharmaceutical preparations for the treatment of cancer; and pharmaceutical preparations for use in oncology
adzenys xr-odt

General Information

Serial Number86847760
Word MarkADZENYS XR-ODT
Filing DateMonday, December 14, 2015
Status701 - SECTION 8 - ACCEPTED
Status DateMonday, September 26, 2022
Registration Number5147879
Registration DateTuesday, February 21, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 7, 2016

Trademark Statements

Goods and ServicesPrescription pharmaceutical preparations for the treatment of disease and disorders of the central nervous system, excluding pharmaceutical preparations for the prevention and treatment of disorders of the immune system; pharmaceutical preparations for the treatment of cancer; and pharmaceutical preparations for use in oncology
Disclaimer with Predetermined Text"XR-ODT"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 17, 2015
Primary Code005
First Use Anywhere DateMonday, April 25, 2016
First Use In Commerce DateMonday, April 25, 2016

Trademark Owner History

Party NameNeos Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDenver, CO 80237
Party NameNeos Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGrand Prairie, TX 75050
Party NameNeos Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGrand Prairie, TX 75050

Trademark Events

Event DateEvent Description
Tuesday, October 10, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 10, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, October 10, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 10, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, October 10, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, September 27, 2022NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Monday, September 26, 2022REGISTERED - SEC. 8 (6-YR) ACCEPTED
Monday, September 26, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, April 12, 2022TEAS SECTION 8 RECEIVED
Monday, February 21, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, April 1, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 1, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 1, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, April 1, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 1, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 1, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, August 13, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 13, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 21, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, January 17, 2017NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, January 16, 2017ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, January 4, 2017STATEMENT OF USE PROCESSING COMPLETE
Thursday, December 8, 2016USE AMENDMENT FILED
Wednesday, January 4, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 8, 2016TEAS STATEMENT OF USE RECEIVED
Tuesday, August 2, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 7, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 7, 2016PUBLISHED FOR OPPOSITION
Wednesday, May 18, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, April 29, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, April 21, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 21, 2016EXAMINER'S AMENDMENT ENTERED
Wednesday, April 20, 2016ASSIGNED TO LIE
Tuesday, April 19, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, April 19, 2016EXAMINERS AMENDMENT E-MAILED
Tuesday, April 19, 2016EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 30, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 30, 2016NON-FINAL ACTION E-MAILED
Wednesday, March 30, 2016NON-FINAL ACTION WRITTEN
Wednesday, March 30, 2016ASSIGNED TO EXAMINER
Thursday, December 17, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 17, 2015NEW APPLICATION ENTERED

Related Keywords

adzenys pharmaceutical preparations treatment disorders system immune oncology prevention cancer central